Navigation Links
Nektar Therapeutics Reports First Quarter 2011 Financial Results
Date:4/27/2011

as a once-daily, oral tablet for the treatment of opioid-induced constipation.  The agreement also includes NKTR-119, an earlier stage development program that is a co-formulation of NKTR-118 and an opioid.  NKTR-181, a novel mu-opioid analgesic molecule, is being evaluated in Phase 1 clinical studies.  In oncology, NKTR-102, a novel topoisomerase I-inhibitor, is being evaluated in Phase 2 clinical studies for the treatment of breast, ovarian and colorectal cancers.  NKTR-105, a novel anti-mitotic agent, is in a Phase 1 clinical study in cancer patients with refractory solid tumors.

Nektar's technology has enabled seven approved products in the U.S. or Europe through partnerships with leading biopharmaceutical companies, including UCB's Cimzia® for Crohn's disease and rheumatoid arthritis, Roche's PEGASYS® for hepatitis C and Amgen's Neulasta® for neutropenia.

Nektar is headquartered in San Francisco, California, with additional R&D operations in Huntsville, Alabama and Hyderabad, India. Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com.

This press release contains forward-looking statements that reflect management's current views regarding the value and potential of Nektar's drug candidate pipeline, the value and potential of Nektar's technology platform, and the value and potential of certain of Nektar's collaborations with third parties.  These forward-looking statements involve numerous risks and uncertainties, including but not limited to: (i) Nektar's product candidates and those of its collaboration partners are in various stages of clinical development and the risk of failure is high and can unexpectedly occur at any stage prior to regulatory approval for numerous reasons including safety and efficacy findings even after positive findings in preclinical and clinical studie
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Dennis Winger Joins Nektar Therapeutics Board of Directors
2. Nektar Therapeutics Reports Third Quarter 2009 Financial Results
3. Nektar to Announce Financial Results for the Third Quarter of 2009 on Wednesday, November 4, 2009, After Close of U.S.-Based Financial Markets
4. Nektar Therapeutics to Host Conference Call to Discuss Todays Announcement of a New Partnership for NKTR-118 and NKTR-119
5. AstraZeneca and Nektar Sign Worldwide Agreement for Nektar Drug Development Programmes -- NKTR-118 and NKTR-119 -- to Address Opioid-Induced Constipation
6. Nektar Therapeutics to Present at the BMO Capital Markets 9th Annual Focus on Healthcare Conference in New York City
7. Nektar to Announce Financial Results for the Second Quarter of 2009 on Tuesday, August 4, 2009, After Close of U.S.-Based Financial Markets
8. Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Chief Medical Officer
9. Nektar Therapeutics Reports First Quarter 2009 Financial Results
10. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the 29th Annual Cowen and Company Healthcare Conference in Boston
11. Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... 22, 2014 This is a professional ... M-Phenylenediamine (mPDA) industry in Global and China. The ... definitions, applications and industry chain structure. Global market analysis ... focus on history, developments, trends and competitive landscape of ... situation is also offered. , The report also focuses ...
(Date:9/22/2014)... Research and Markets has announced ... Cellulose Industry Report 2014" report to their offering. ... Industry Report 2014 is a professional and in-depth study ... industry with a focus on the Chinese situation. ... industry including definitions, classifications, applications and industry chain structure. ...
(Date:9/22/2014)...  WIRB-Copernicus Group (WCG), the world,s largest provider ... research, announced today that its Western Institutional Review ... the Association for the Accreditation of Human Research ... for clinical research participants. WCG Chairman ... commented, "It is of utmost importance to WCG ...
(Date:9/21/2014)... Switzerland have succeeded in observing the "forbidden" infrared ... time. These extremely weak spectra offer perspectives for ... also contribute to the development of molecular clocks ... the scientific journal Nature Physics . , ... and light, is probably the most important method ...
Breaking Biology Technology:m-Phenylenediamine Industry: mPDA Global & China Trend Analysis Now Available at ReportsnReports.com 2m-Phenylenediamine Industry: mPDA Global & China Trend Analysis Now Available at ReportsnReports.com 3Global and Chinese Microcrystalline Cellulose Industry Report 2014 2Western IRB (WIRB) Awarded AAHRPP Reaccreditation 2Uncovering the forbidden side of molecules 2
... May 29 Sangamo BioSciences,Inc. (Nasdaq: SGMO ... CEO, will provide an update on Sangamo,s diabetic ... 6, 2008, at the Canaccord Adams,Diabetes and Obesity ... be webcast live and may be accessed via ...
... 29 Diplomat Specialty,Pharmacy, a leader in specialty ... (DTM) announced today that their specialty,pharmacy was one ... Roundtable,(NMCRT) held this month in Dallas, Texas. This ... managed care organizations together to,review and improve on ...
... NanoBio(R) Corporation, a,biopharmaceutical company focused on developing ... of infectious diseases, today,announced the appointment of David ... most recently served as President of Pharmaceutical Operations ... David to our Board of Directors and look,forward ...
Cached Biology Technology:Sangamo BioSciences to Present at the Canaccord Adams Diabetes and Obesity Conference 2Diplomat Specialty Pharmacy Sponsors National Managed Care Roundtable for Industry Executive Advisory Board 2David M. Stout Joins NanoBio Corporation's Board of Directors 2
(Date:9/21/2014)... autism are significantly less likely to report taking iron ... of children who are developing normally, a study by ... , Low iron intake was associated with a five-fold ... mother was 35 or older at the time of ... conditions such as obesity hypertension or diabetes. , The ...
(Date:9/21/2014)... MA -- In recent years, new strains of bacteria ... Each year, these superbugs, including drug-resistant forms of tuberculosis ... and kill at least 23,000. Despite the urgent need ... classes of antibiotics in the past decade. , MIT ... these superbugs. Using a gene-editing system that can disable ...
(Date:9/19/2014)... Jimmy Durante of dinosaurs a newly discovered ... new dinosaur, named Rhinorex condrupus by ... Young University, lived in what is now Utah ... Cretaceous period. , Rhinorex, which translates roughly into ... relative of other Cretaceous hadrosaurs like Parasaurolophus and ...
Breaking Biology News(10 mins):Mothers of children with autism less likely to have taken iron supplements 2Battling superbugs 2Battling superbugs 3Battling superbugs 4New hadrosaur noses into spotlight 2
... in New Guinea, one of which is the new smallest known ... issue of the online journal PLoS ONE , and the ... University. The new smallest vertebrate species is called Paedophryne ... it was found. The adult body size for these frogs ranges ...
... gene 15 (ISG15), a ubiquitin like protein, is highly ... How the elevated ISG15 pathway contributes to tumorigenic phenotypes ... published in the January 2012 issue of Experimental ... her co-investigators from the Louisiana State University School of ...
... humans arrive in Europe and Asia? At what rate have ... How did Neanderthal teeth and bones differ from ours? These ... Max Planck Weizmann Institute of Science Center in the ... the establishment of the Center is being signed today at ...
Cached Biology News:ISG15: A novel therapeutic target to slow breast cancer cell motility 2Weizmann Institute and Max Planck Society establish a joint center for archaeology and anthropology 2Weizmann Institute and Max Planck Society establish a joint center for archaeology and anthropology 3Weizmann Institute and Max Planck Society establish a joint center for archaeology and anthropology 4
Mouse monoclonal [SIT-01] to SIT ( Abpromise for all tested applications). entrezGeneID: 27240 SwissProtID: Q9Y3P8...
Anti-MMP-25 (Membrane-type MMP-6, Mt6MMP), hinge region; rabbit host...
Anti-MMP-25 (Membrane-type MMP-6, Mt6MMP), hinge region; rabbit host...
Anti-MMP-25 (Membrane-type MMP-6, Mt6MMP), hinge region; rabbit host...
Biology Products: